185 related articles for article (PubMed ID: 38502143)
41. Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline
Desai NV; Tan AR
JCO Precis Oncol; 2023 May; 7():e2200446. PubMed ID: 37163718
[TBL] [Abstract][Full Text] [Related]
42. Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
Dawood S; Konstantinova M; Perazzo F; Kim SB; Villarreal-Garza C; Franco SX; Simon SD; El-Nahas T
Chin Clin Oncol; 2020 Oct; 9(5):61. PubMed ID: 32819114
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells.
Guney Eskiler G; Ozturk M
Cell Signal; 2022 Mar; 91():110229. PubMed ID: 34958867
[TBL] [Abstract][Full Text] [Related]
44. Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
[TBL] [Abstract][Full Text] [Related]
45. A Progressively Disassembled DNA Repair Inhibitors Nanosystem for the Treatment of BRCA Wild-Type Triple-Negative Breast Cancer.
Fang W; Wang J; Ma X; Shao N; Ye K; Zhang D; Shi C; Luo L
Int J Nanomedicine; 2023; 18():6001-6019. PubMed ID: 37901361
[TBL] [Abstract][Full Text] [Related]
46. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
[TBL] [Abstract][Full Text] [Related]
47. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
48. Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective.
Verheij M; Vens C; van Triest B
Drug Resist Updat; 2010; 13(1-2):29-43. PubMed ID: 20167530
[TBL] [Abstract][Full Text] [Related]
49. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
50. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
Al-Ejeh F; Shi W; Miranda M; Simpson PT; Vargas AC; Song S; Wiegmans AP; Swarbrick A; Welm AL; Brown MP; Chenevix-Trench G; Lakhani SR; Khanna KK
J Nucl Med; 2013 Jun; 54(6):913-21. PubMed ID: 23564760
[TBL] [Abstract][Full Text] [Related]
51. Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer?
Césaire M; Thariat J; Candéias SM; Stefan D; Saintigny Y; Chevalier F
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30487462
[TBL] [Abstract][Full Text] [Related]
52. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
[TBL] [Abstract][Full Text] [Related]
53. Triple negative breast cancer: new therapeutic approaches and BRCA status.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
APMIS; 2018 May; 126(5):371-379. PubMed ID: 29696717
[TBL] [Abstract][Full Text] [Related]
54. Characteristics of triple-negative breast cancer.
de Ruijter TC; Veeck J; de Hoon JP; van Engeland M; Tjan-Heijnen VC
J Cancer Res Clin Oncol; 2011 Feb; 137(2):183-92. PubMed ID: 21069385
[TBL] [Abstract][Full Text] [Related]
55. Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors.
Li J; Lan M; Peng J; Xiong Q; Xu Y; Yang Y; Zhou Y; Liu J; Zeng Z; Yang X; Zhang Z; Zhang P; Zhu Q; Wu W
Genes (Basel); 2022 Apr; 13(5):. PubMed ID: 35627188
[TBL] [Abstract][Full Text] [Related]
56. PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation.
Michmerhuizen AR; Pesch AM; Moubadder L; Chandler BC; Wilder-Romans K; Cameron M; Olsen E; Thomas DG; Zhang A; Hirsh N; Ritter CL; Liu M; Nyati S; Pierce LJ; Jagsi R; Speers C
Mol Cancer Ther; 2019 Nov; 18(11):2063-2073. PubMed ID: 31413177
[TBL] [Abstract][Full Text] [Related]
57. Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer.
Sayed-Ahmed MM; Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Aleisa AM; Al-Yahya AA; Alsheikh A; Al Diab AI; Al-Akeely MH
Tumori; 2013; 99(4):545-54. PubMed ID: 24326846
[TBL] [Abstract][Full Text] [Related]
58. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.
Khosravi-Shahi P; Cabezón-Gutiérrez L; Custodio-Cabello S
Asia Pac J Clin Oncol; 2018 Feb; 14(1):32-39. PubMed ID: 28815913
[TBL] [Abstract][Full Text] [Related]
59. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
[TBL] [Abstract][Full Text] [Related]
60. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
